Repinotan

Repinotan
(IUPAC) ime
	(R)-(-)-2-[4-[(hroman-2-ilmetil)-amino]-butil]-1,1-diokso-benzo[d]izotiazolon
Klinički podaci
Identifikatori
CAS broj	144980-29-0
ATC kod	nije dodeljen
PubChem	198757
UNII	05PB82Z52L
ChEMBL	CHEMBL1614652
Hemijski podaci
Formula	C21H24N2O4S
Mol. masa	400,491 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C21H24N2O4S/c24-21-18-8-2-4-10-20(18)28(25,26)23(21)14-6-5-13-22-15-17-12-11-16-7-1-3-9-19(16)27-17/h1-4,7-10,17,22H,5-6,11-15H2/t17-/m1/s1 ; Key: YGYBFMRFXNDIPO-QGZVFWFLSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Nije kontrolisana supstanca
Način primene	Oralno

Repinotan (BAYx3702) je selektivni pun agonist 5-HT_1A receptor visoke potentnosti i efikasnosti.^[4]^[5] On ima neuroprotektivno dejstvo u životinjskim studijama,^[6]^[7]^[8] i bio je u kliničkim ispitivanjima za primenu u redukovanju oštećenja mozga nakon povrede glave.^[9] Naknadno je ispitivan u fazi II za tretman moždanog udara. Dok su nuspojave bile blage i sastojale se uglavnom od mučnine, repinotan nije bio dovoljno efikasan da bi se opravdala dalja klinička ispitivanja.^[10]^[11]^[12]

Repinotan se i dalje istražuje za druge moguće primene. Utvrđeno je da je efektivan za tretiranje respiratorne depresije proizvedene morfinom, mada u proizvodi malo umanjenje analgetskog dejstva.^[13]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ De Vry, J.; Schohe-Loop, R.; Heine, H. G.; Greuel, J. M.; Mauler, F.; Schmidt, B.; Sommermeyer, H.; Glaser, T. (1998). „Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist”. The Journal of Pharmacology and Experimental Therapeutics 284 (3): 1082–1094. PMID 9495870.
↑ Dong, J.; De Montigny, C.; Blier, P. (1998). „Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe”. The Journal of Pharmacology and Experimental Therapeutics 286 (3): 1239–1247. PMID 9732384.
↑ Alessandri, B.; Tsuchida, E.; Bullock, R. M. (1999). „The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat”. Brain Research 845 (2): 232–235. DOI:10.1016/S0006-8993(99)01948-4. PMID 10536203.
↑ Kline, A. E.; Yu, J.; Horváth, E.; Marion, D. W.; Dixon, C. E. (2001). „The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats”. Neuroscience 106 (3): 547–555. DOI:10.1016/S0306-4522(01)00300-1. PMID 11591455.
↑ Mauler, F.; Horváth, E. (2005). „Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury”. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 25 (4): 451–459. DOI:10.1038/sj.jcbfm.9600038. PMID 15674237.
↑ Ohman, J.; Braakman, R.; Legout, V.; Traumatic Brain Injury Study Group (2001). „Repinotan (BAY x 3702): a 5HT1A agonist in traumatically brain injured patients”. Journal of neurotrauma 18 (12): 1313–1321. DOI:10.1089/08977150152725614. PMID 11780862.
↑ Lutsep, H. L. (2005). „Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke”. Current drug targets. CNS and neurological disorders 4 (2): 119–120. DOI:10.2174/1568007053544165. PMID 15857296.
↑ Berends, A. C.; Luiten, P. G.; Nyakas, C. (2005). „A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke”. CNS Drug Reviews 11 (4): 379–402. DOI:10.1111/j.1527-3458.2005.tb00055.x. PMID 16614737.
↑ Teal, P.; Davis, S.; Hacke, W.; Kaste, M.; Lyden, P.; Modified Randomized Exposure Controlled Trial Study Investigators; Fierus, M.; Bayer Healthcare, A. (2009). „A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)”. Stroke; a journal of cerebral circulation 40 (11): 3518–3525. DOI:10.1161/STROKEAHA.109.551382. PMID 19745176.
↑ Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, Putensen C, Hoeft A (October 2010). „Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats”. Anesthesia and Analgesia 111 (4): 901–7. DOI:10.1213/ANE.0b013e3181eac011. PMID 20802053.

Povezano

Robalzotan

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[4] De Vry, J.; Schohe-Loop, R.; Heine, H. G.; Greuel, J. M.; Mauler, F.; Schmidt, B.; Sommermeyer, H.; Glaser, T. (1998). „Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist”. The Journal of Pharmacology and Experimental Therapeutics 284 (3): 1082–1094. PMID 9495870.

[5] Dong, J.; De Montigny, C.; Blier, P. (1998). „Full agonistic properties of BAY x 3702 on presynaptic and postsynaptic 5-HT1A receptors electrophysiological studies in the rat hippocampus and dorsal raphe”. The Journal of Pharmacology and Experimental Therapeutics 286 (3): 1239–1247. PMID 9732384.

[6] Alessandri, B.; Tsuchida, E.; Bullock, R. M. (1999). „The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat”. Brain Research 845 (2): 232–235. DOI:10.1016/S0006-8993(99)01948-4. PMID 10536203.

[7] Kline, A. E.; Yu, J.; Horváth, E.; Marion, D. W.; Dixon, C. E. (2001). „The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats”. Neuroscience 106 (3): 547–555. DOI:10.1016/S0306-4522(01)00300-1. PMID 11591455.

[8] Mauler, F.; Horváth, E. (2005). „Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury”. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 25 (4): 451–459. DOI:10.1038/sj.jcbfm.9600038. PMID 15674237.

[9] Ohman, J.; Braakman, R.; Legout, V.; Traumatic Brain Injury Study Group (2001). „Repinotan (BAY x 3702): a 5HT1A agonist in traumatically brain injured patients”. Journal of neurotrauma 18 (12): 1313–1321. DOI:10.1089/08977150152725614. PMID 11780862.

[10] Lutsep, H. L. (2005). „Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke”. Current drug targets. CNS and neurological disorders 4 (2): 119–120. DOI:10.2174/1568007053544165. PMID 15857296.

[11] Berends, A. C.; Luiten, P. G.; Nyakas, C. (2005). „A review of the neuroprotective properties of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke”. CNS Drug Reviews 11 (4): 379–402. DOI:10.1111/j.1527-3458.2005.tb00055.x. PMID 16614737.

[12] Teal, P.; Davis, S.; Hacke, W.; Kaste, M.; Lyden, P.; Modified Randomized Exposure Controlled Trial Study Investigators; Fierus, M.; Bayer Healthcare, A. (2009). „A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT)”. Stroke; a journal of cerebral circulation 40 (11): 3518–3525. DOI:10.1161/STROKEAHA.109.551382. PMID 19745176.

[pmid20802053-13] Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, Putensen C, Hoeft A (October 2010). „Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats”. Anesthesia and Analgesia 111 (4): 901–7. DOI:10.1213/ANE.0b013e3181eac011. PMID 20802053.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]